Indian Pharmaceutical Supplier to Egypt.
Egypt is the largest pharmaceutical market in Africa and, alongside Saudi Arabia, one of the two anchor markets of the MENA pharma economy. With more than 105 million people, a fast-expanding Universal Health Insurance Authority (UHIA) programme, a deep domestic generics manufacturing base and an Egyptian Drug Authority (EDA) that actively regulates imports where local capacity gaps exist, it is one of the highest-value destinations an Indian pharmaceutical supplier can register into. Public tertiary demand runs through Cairo University Hospital (Kasr Al-Aini), Ain Shams University Hospital and Mansoura University Hospital; private-sector demand sits with Cleopatra Hospitals Group, Alfa Cure Oncology Center, As-Salam International Hospital and Dar Al Fouad Hospital. Products enter through Cairo International Airport (CAI), Borg El Arab (HBE) in Alexandria, and Alexandria Port by sea. Our Mumbai regulatory desk files directly with EDA; our Dubai commercial desk handles on-ground MENA coordination with Egyptian importers and hospital groups.
EDA: a serious regulator running Africa's largest pharma register.
The Egyptian Drug Authority was established by Presidential Decree in 2019 as a standalone regulator, consolidating functions that previously sat inside the Ministry of Health's Central Administration of Pharmaceutical Affairs and the National Organisation for Drug Control and Research. EDA now holds combined authority over pharmaceutical registration, GMP inspection, pharmacovigilance and pricing. The practical consequence for an Indian supplier is a cleaner single-window interface, electronic submissions and a steadier review cadence than the pre-2019 landscape.
Timelines land at 14 to 22 months for a WHO-GMP-sourced generic with a clean dossier, API DMF and stability covering six months accelerated plus twelve months real-time. EDA accepts ICH CTD submissions with an Egypt-specific Module 1: Arabic SmPC, Arabic PIL, CoPP on WHO format, GMP certificate, facility site master file summary and pricing documentation benchmarked to EDA's reference-country basket. Biologics and biosimilars require local batch-release testing or an EDA-recognised agreement, and run 24 to 36 months. Variations and pack-size extensions typically clear in six to ten months.
EDA pricing is strictly regulated. The price committee benchmarks against a defined reference basket and applies mandatory pack-size and therapeutic-comparator rules. Importers should budget for the pricing review explicitly; an approved dossier without a workable price decision is not a commercial product. We structure the commercial schedule with the Egyptian importer-of-record before filing, so the price position EDA will accept is anchored to a real distributor landed-cost model rather than a theoretical ex-works price.
Arabic labelling is mandatory: bilingual outer carton, Arabic PIL and Arabic SmPC, with EDA artwork review and approval before print. Controlled substances run under an EDA narcotic-control permit issued in line with INCB quotas, and the Egyptian importer of record must hold a current narcotic licence. Serialisation and 2D-barcode traceability are being rolled out progressively across UHIA-tendered lines.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capabilities, shaped around Africa's largest pharma market.
EDA dossier preparation and filing
ICH CTD dossiers with Egypt-specific Module 1, Arabic SmPC and PIL, CoPP on WHO format, GMP certificate, pricing pack benchmarked to the EDA reference basket, and e-submission through the EDA portal. Variations and renewals tracked on a shared calendar with the Egyptian importer of record.
UHIA and public-tender response
Technical and commercial pack tuned to Universal Health Insurance Authority tenders and the university-hospital procurement calendar: EDA number, CoA, CoO, GMP, PSUR, stability, Arabic artwork and a price schedule aligned to EDA pricing rules and UHIA formulary priorities.
University hospital supply
Contract supply to Cairo University Hospital (Kasr Al-Aini), Ain Shams University Hospital, Mansoura University Hospital and the Alexandria academic network. Batch-level traceability, CoA and CoO on every dispatch, and pharmacovigilance support for each approved SKU.
Private hospital and oncology supply
Contract supply to Cleopatra Hospitals Group, Alfa Cure Oncology Center, As-Salam International Hospital and Dar Al Fouad Hospital, with a portfolio heavy in oncology injectables, supportive care, antibiotics, cardiometabolic and women's-health lines.
Arabic bilingual artwork
EDA-compliant Arabic typesetting with native-speaker medical review, outer-carton bilingual layout, PIL and SmPC translation, and artwork proof secured with EDA before any print run commits. Aligned to Egyptian script conventions, not generic Gulf Arabic layouts.
Essential medicines and shortage response
Where EDA flags an essential-medicines shortage or a fast-track priority, we prioritise Indian WHO-GMP-sourced supply with compressed artwork, CoPP and batch-release lead times, and coordinate directly with the EDA priority-medicines desk through our Mumbai regulatory team.
Mumbai to Cairo in under six hours, Alexandria sea-freight for volume.
Air freight: BOM-CAI is a block time of roughly five hours forty minutes, with EgyptAir and Air India as the primary carriers, and Gulf-hub routings via DXB, AUH and DOH consistently available on days where a direct slot is tight. HBE (Borg El Arab) covers secondary Alexandria-region demand. Door-to-door for ambient pharmaceutical cargo clears in three to five working days; EDA import clearance at CAI is handled through the Nafeza single-window advanced cargo platform, and our nominated freight agent resolves landing-side queries.
Sea freight: Nhava Sheva to Alexandria Port runs a fifteen-to-twenty-day transit, with weekly feeder sailings from MSC, CMA CGM, ONE and Hapag-Lloyd, most trans-shipped through Jeddah, Salalah, Port Said East or Jebel Ali. Alexandria Port handles the bulk of Egyptian pharmaceutical sea cargo, with Damietta and East Port Said as alternate discharge points. Less-than-container-load consolidation is available for orders below 10 CBM.
Cold-chain: Envirotainer RAP e2 and RKN e1 for 2-8 degrees active, va-Q-tec passive for 15-25 ambient, and continuous temperature logging on every consignment with invoice value above USD 15,000. Egyptian summer temperatures drive us toward night-arrival slots at CAI for 2-8 product, with Dubai or Jeddah positioning as a 24-to-48-hour fallback where the direct CAI cool-dolly slot is full. Insurance on Institute Cargo Clauses A, door-to-door.
Payment terms: TT 30% advance and 70% against scanned Bill of Lading for first-time customers, or sight LC through Commercial International Bank (CIB), National Bank of Egypt, QNB Alahli or HSBC Egypt. Repeat customers move to open account at 60 to 90 days after five clean shipments, subject to credit-insurer cover. Currency volatility of the Egyptian pound against USD is a material consideration; we price in USD with clear FX-clause language in the sales contract.
What Egyptian hospitals, UHIA and the oncology network actually order.
Cardiometabolic is the volume driver. Egyptian adult diabetes prevalence tracks above 20% in several age bands and cardiovascular disease is the leading cause of mortality; UHIA and university-hospital procurement pulls through statins, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 analogues where locally affordable, ARBs, beta-blockers, long-acting insulin analogues and the full hypertension formulary. Hepatology carries a distinctive Egyptian signature: the national hepatitis C elimination campaign remains the most-cited public-health victory of the past decade and the surveillance-and-treatment infrastructure still pulls through anti-viral and hepatology supportive-care lines.
Oncology is the second-largest draw. Alfa Cure Oncology Center, Cleopatra's oncology units and the Baheya Foundation anchor breast-cancer and solid-tumour demand; volume is steady on trastuzumab, rituximab, bevacizumab and pertuzumab biosimilars, capecitabine, tamoxifen, aromatase inhibitors, pegfilgrastim and the standard supportive-care suite. Critical-care injectables (noradrenaline, vasopressin, propofol, midazolam), broad-spectrum antibiotics (piperacillin-tazobactam, meropenem, linezolid), ophthalmology, dermatology and maternal-health lines round out the hospital roster.
Every line ships with EDA-compliant bilingual labelling, pricing-committee-compliant commercial schedules and CoA-per-batch documentation.
A Middle-East-focused sponsor used M Care in 2024 to run the EDA filing and initial UHIA tender entry for a four-SKU cardiometabolic bundle. We submitted the Egyptian dossiers eight weeks after brief, cleared EDA queries in two cycles, and obtained marketing authorisations across a 16-to-19-month window. The UHIA tender response went in the same quarter as the last MA issue and the first commercial shipment landed at Alexandria on a CMA CGM sailing three weeks after PO. Cumulative consignments across the first year: eleven, with zero regulatory queries in-market and zero temperature excursions. The sponsor has since expanded the same bundle into Tunisia and Algeria, with the Egyptian dossiers as anchor reference.
Why Indian pharma, why M Care, and what an Egyptian buyer actually receives.
Egypt has one of the most mature pharmaceutical ecosystems in Africa, with a large domestic manufacturing base, a sophisticated university-hospital system, and a regulator that treats imports as a complement to local supply rather than an adversary. Indian manufacturing fits this shape well: WHO-GMP capacity covers roughly a fifth of global generic finished-dosage-form volume, API unit economics allow competitive pricing even inside the tight EDA reference-basket envelope, and ICH-aligned dossiers move through EDA's e-submission pipeline more predictably than submissions that mix regional and international formats.
The question most Egyptian buyers and their institutional sponsors ask is how to navigate the pricing committee and the UHIA roll-out in a way that does not compress margin to zero. M Care's Mumbai head office handles the regulatory and CMC engine: dossier writing, stability coordination, pharmacovigilance and CoPP procurement, with EDA e-submission readiness from the first file. Our Dubai commercial desk manages the Egyptian importer-of-record relationship, price-committee strategy, tender timing and the multi-governorate distribution reality. Treating Egypt as a strategic market rather than a transactional opportunity is the single biggest lever a sponsor has over the real landed margin.
Three specifics make the relationship different. First, a single named account manager who owns the file from the first EDA submission through the price-committee decision, the UHIA tender, and the onward renewals and variations. Second, a pricing model built around real distributor economics, not ex-works fiction: we reverse-engineer the maximum ex-works price that allows the Egyptian importer and wholesaler to meet EDA's pharmacy and hospital price points, and we build the commercial schedule from there. Third, realistic expectations on timelines. We say 14 to 22 months for an EDA generic because that is what clean submissions actually run end-to-end including pricing, and we do not over-claim fast-track access except where the molecule genuinely qualifies under EDA's essential-medicines priority schemes.
One practical note for first-time Egyptian buyers: the EDA register is large and competitive, and the price committee will benchmark any new filing against existing registrations in the same therapeutic slot. A new Indian SKU with no differentiation versus an already-registered Indian or local SKU will struggle to earn a workable price decision. We start every Egypt brief with a competitive-landscape note so the sponsor can decide whether the SKU has a real commercial path before the dossier spend begins.
Egypt pharmaceutical import: common questions.
Which authority registers pharmaceutical products in Egypt?
The Egyptian Drug Authority (EDA), a standalone regulator established by Presidential Decree in 2019, with combined authority over pharmaceutical registration, GMP inspection, pharmacovigilance and pricing. EDA issues the registration number that appears on every imported commercial pack.
How long does EDA registration typically take?
Fourteen to twenty-two months end-to-end for a WHO-GMP-sourced generic with a clean dossier, including the pricing committee review and Arabic artwork approval. Biologics, biosimilars and new chemical entities run 24 to 36 months.
Is Arabic labelling mandatory in Egypt?
Yes. Bilingual Arabic and English outer carton, Arabic PIL and Arabic SmPC, with EDA artwork approval before any print run. We commission the Arabic typesetting, run native-speaker medical review and secure EDA sign-off as part of the pre-shipment pack.
How is EDA pricing determined?
EDA's pricing committee benchmarks each new registration against a defined reference-country basket, applies mandatory pack-size and therapeutic-comparator rules, and issues a maximum retail price. The price decision is a distinct step after marketing authorisation and is mandatory before commercial launch. We build the commercial schedule from the distributor-economics side before filing.
What is UHIA and why does it matter?
UHIA is the Universal Health Insurance Authority, the phased national insurance programme rolling out governorate by governorate across Egypt. UHIA pulls substantial formulary demand through competitive tendering. A strong EDA registration combined with a disciplined tender response is the principal commercial path for institutional volume.
What cold-chain routes do you use into Egypt?
BOM-CAI direct on EgyptAir and Air India, with Envirotainer or va-Q-tec containers and continuous temperature logging, plus Gulf-hub fallback routings via DXB, AUH and DOH. Alexandria Port for high-volume ambient sea freight. Insurance on Institute Cargo Clauses A, door-to-door.
How is payment typically structured with Egyptian importers?
First-time: TT 30% advance, 70% against scanned Bill of Lading, or a sight LC through CIB, National Bank of Egypt, QNB Alahli or HSBC Egypt. Repeat customers, post five clean shipments, move to open account at 60 to 90 days depending on volume and credit-insurer cover. USD pricing with explicit FX-clause language in the sales contract to manage Egyptian pound volatility.
Why buyers choose M Care for the India → Egypt corridor.
EDA fluency
Dossiers built to the exact format EDA reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → CAI direct air for time-critical orders, and Alexandria for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in Egypt.
Top categories we ship to Egypt
Anti-infectives
Penicillins, cephalosporins, carbapenems, antivirals, antimalarials — 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
Oncology
Cytotoxics, targeted therapy and supportive care — bortezomib, docetaxel, paclitaxel, gemcitabine.
Diabetes & endocrine
Insulins, oral antidiabetics, thyroid and hormonal therapy — 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals — 1,283 SKUs, our broadest catalogue.
Molecule, volume, target buyer. One working day to a quote.
Your enquiry goes directly to the account manager responsible for Egypt. No call-centre hops, no generic autoresponders, just the answer your procurement file needs.
Start an Egypt enquiry → Back to all markets